Cover Image
Market Research Report

Market Spotlight: Zika Virus

Published by Datamonitor Healthcare Product code 594575
Published Content info 27 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Zika Virus
Published: February 20, 2019 Content info: 27 Pages
Description

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, and licensing and acquisition deals.

Key Takeaways

  • The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.
  • In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.
  • The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.
  • Therapies in early-to-mid-stage development for Zika virus focus on the immune system and viral antigens. Candidates comprise DNA vaccines such as the National Institutes of Health's Zika Virus Vaccine, GeneOne's GLS-5700, and Inovio's INO-A002; Moderna's mRNA vaccine; Themis Bioscience's recombinant viral vector vaccine; Imutex's AGS-v vaccine; Johnson & Johnson's Ad26.ZIKV.001 vaccine; Takeda's TAK-426 vaccine; Emergent BioSolutions' ZIKV-IG; and Valneva's ZIKV-VLA1601.
  • The overall likelihood of approval of a Phase I antiviral asset is 16.2%, and the average probability a drug advances from Phase III is 75.9%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
  • There have been 10 licensing and asset acquisition deals involving Zika virus drugs during 2014-19, all of which occurred in either 2016 or 2017. The exclusive 2017 agreement between Emergent BioSolutions and Valneva worth $58.3m for the global rights to Valneva's Zika vaccine technology and ZIKV-VLA1601 was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Zika virus have been in Phase I.
  • The US leads the number of Zika virus clinical trials globally. The largest share of industry-sponsored clinical trials are ongoing. Takeda and GeoVax have planned one trial each in the Zika virus space.
  • Sanofi leads industry sponsors with three clinical trials for Zika virus, although all of its trials have been terminated.
Table of Contents
Product Code: DMKC0180743

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Vaccines
  • Therapeutics

EPIDEMIOLOGY

PIPELINE DRUGS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GeoVax Collaborates With Enesi Pharma On Needle-Free Vaccines
  • Bridging The Gap: Cyclenium Pharma
  • Brazil's Oneway Diagnostica, iBio Collaborate On Virus Diagnostics

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Recent epidemiological updates
  • Figure 2: Zika cases timeline
  • Figure 3: Overview of pipeline drugs for Zika virus in the US
  • Figure 4: Pipeline drugs for Zika virus, by company
  • Figure 5: Pipeline drugs for Zika virus, by drug type
  • Figure 6: Pipeline drugs for Zika virus, by classification
  • Figure 7: Probability of success in the Zika virus pipeline
  • Figure 8: Licensing and asset acquisition deals in Zika virus, 2014-19
  • Figure 9: Clinical trials in Zika virus
  • Figure 10: Top 10 drugs for clinical trials in Zika virus
  • Figure 11: Top 10 companies for clinical trials in Zika virus
  • Figure 12: Zika virus trial locations
  • Figure 13: Zika virus trials status
  • Figure 14: Zika virus trials sponsors, by phase

LIST OF TABLES

  • Table 1: Pipeline drugs for Zika virus in the US
Back to Top